Has Carolina Ionete, MD received payments from drug or device companies?

Yes. Drug and device makers reported $144,222 in general payments to Carolina Ionete, MD across 68 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Carolina Ionete, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Carolina Ionete, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Carolina Ionete, MD

Neurology · Worcester, MANPI 1386650190

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $125,433 of the $144,222 with a category attached, or 87.0%. 11 manufacturers reported payments, led by Sanofi at 45.8% of the total. Reporting peaked in 2021 at $69,942 and has fallen 99.8% since, to $159 in 2025. Among neurology clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$144,222in general payments, 2019–2025

Across 68 payments — averaging $2120.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Sanofi$66K
Sanofi US Services Inc.$64K
AstraZeneca$4K
E.r. Squibb & Sons, L.L.C.$4K
F. Hoffmann-la Roche AG$2K
EMD Serono, Inc.$2K
plus $3K from 5 others

$2,327,178in research payments, 2019–2025

Across 216 payments — averaging $10,774 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Genentech, Inc.$2.1M
Novartis$131K
Biogen$76K
Sanofi$23K
F. Hoffmann-la Roche AG$2K

What the payments were for

Consulting fees$125,43387%
Speaking & faculty fees$7,9025%
Travel & lodging$8,1806%
Food & beverage$1,6141%
Education$1,0921%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Sanofi	36	$66,047
Sanofi US Services Inc.	6	$64,069
AstraZeneca	6	$4,010
E.r. Squibb & Sons, L.L.C.	3	$3,917
F. Hoffmann-la Roche AG	5	$2,012
EMD Serono, Inc.	4	$1,590
Banner Life Sciences, LLC	1	$900
Bristol Myers Squibb	2	$813
TG Therapeutics, Inc.	2	$713
Genentech USA, Inc.	2	$112
Genentech, Inc.	1	$38

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

LEMTRADA$78,520
SOLIRIS$3,825
AUBAGIO$2,730
OCREVUS$2,012
Bafiertam$900
ZEPOSIA$719
BRIUMVI$675

How this compares

$144,222 in reported general payments places this provider in the 95th percentile of 761 neurology providers in Massachusetts.

See all neurology providers in Massachusetts →

Medicare billing

Part B allowed, 2024

$48,923

Medicare patients

286

Services billed

467

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
CopaxoneGlatiramer Acetate	41	$239,252
Kesimpta PenOfatumumab	14	$118,738
Avonex Pen (4 Pack)Interferon Beta-1a	13	$105,307
Glatiramer Acetate	30	$67,208
PrivigenImmun Glob G(Igg)/Pro/Iga 0-50	28	$65,991
Emgality PenGalcanezumab-Gnlm	12	$12,626
UbrelvyUbrogepant	11	$11,247
Dalfampridine ErDalfampridine	30	$10,394
Baclofen	113	$2,935
Modafinil	40	$1,467
Gabapentin	91	$1,259
Pregabalin	12	$656
Nortriptyline Hcl	27	$403
Carbamazepine	12	$393
Duloxetine Hcl	14	$324

Paid to pharmacies, not to this prescriber.

Other neurology in Worcester

Herbert MarkleyWorcester$183K
Christopher WrightBoston$2.5M
Shivang JoshiWestborough$1.2M
Egilius SpieringsWellesley Hills$680K
Thomas ScammellBoston$617K
Salvatore NapoliFoxboro$613K
Alfred SandrockBoston$490K
Joshua KatzWellesley$462K
Guy BuckleBrookline$450K
Pushpa NarayanaswamiBoston$420K

See the full list for Massachusetts →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →